Clinical Trial Update: Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Cruris [Phase 3]

View source ↗

Summary

A Phase 3 multicenter trial evaluated the safety and efficacy of NAFT-500 for tinea cruris (jock itch); results from the completed study have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tinea Cruris

Drugs mentioned

• NAFT-500

Snippet

Sponsor: Merz North America, Inc. | Conditions: Tinea Cruris, Jock Itch | Phase 3 | Status: COMPLETED | Results posted: 2012-03-13